A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

drug protocol number
BAY 94-8862 16244
drug sponsor
Bayer
drug study
Finerenone
drug trial site
King Abdulaziz University Hospital (Jeddah)
drug status
Terminated
drug phase